Twist Bioscience Corporation reported a significant increase in revenue for the fiscal year ending September 30, 2025, achieving $376.6 million, a 20% rise from $313.0 million in the previous year. The growth was primarily driven by strong sales in next-generation sequencing (NGS) tools and synthetic genes, with healthcare sector revenues alone contributing $215.1 million. Despite this revenue growth, the company continued to incur net losses, reporting a loss of $77.7 million compared to a loss of $208.7 million in the prior year. The accumulated deficit now stands at $1.32 billion, reflecting ongoing investments in product development and market expansion.
Operationally, Twist Bioscience expanded its customer base to over 3,800, up from 3,550 in the previous year, and shipped approximately 938,000 genes, a 22% increase from the prior year. The company also reported a gross margin improvement to 50.7%, up from 42.6%, attributed to increased revenues and effective cost management strategies. The company’s strategic focus on enhancing its manufacturing capabilities and leveraging its proprietary silicon-based DNA synthesis technology has positioned it favorably within the synthetic biology market.
In a notable strategic move, Twist Bioscience completed the spin-out of its DNA data storage business to Atlas Data Storage, Inc., allowing it to concentrate on its core synthetic biology and NGS products. This transaction included a gain of $48.8 million and is expected to provide future milestone payments and royalties based on Atlas's sales. The company also entered into a Royalty Purchase Agreement with XOMA Royalty, securing $15 million in cash in exchange for future milestone and royalty payments from certain biopharma services agreements.
Looking ahead, Twist Bioscience aims to continue its growth trajectory by expanding its product offerings and market presence, particularly in international markets. The company plans to enhance its operational efficiency and maintain its competitive edge through ongoing research and development initiatives. However, management acknowledges the challenges posed by market conditions and the need for additional financing to support its growth strategy, emphasizing the importance of effective capital management in the coming fiscal periods.
About Twist Bioscience Corp
Twist Bioscience specializes in synthetic DNA and RNA manufacturing using proprietary silicon-based platform technology. Its core products include synthetic genes, oligonucleotide pools, NGS tools, and antibody libraries, serving global research, healthcare, and industrial markets. The company enables applications in drug discovery, diagnostics, materials, agriculture, and data storage, offering high-quality, scalable, and cost-effective solutions with a focus on innovation, sustainability, and regulatory compliance.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.